RecruitingNot ApplicableNCT06266104

Image Enhanced Endoscopy IBD

Image Enhanced Endoscopy Technology to Improve the Detection of Colorectal Dysplasia in Patients With Inflammatory Bowel Disease


Sponsor

Royal Perth Hospital

Enrollment

270 participants

Start Date

Apr 3, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Dye- spray chromoendoscopy remains the recommended gold standard approach for IBD dysplasia surveillance colonoscopy however recently published European and American guidelines recommend either dye-spray or virtual chromoendoscopy can be used for surveillance. The newer Imaged Enhanced Endoscopy technologies TXI and LCI have not formally been evaluated in IBD surveillance in a randomised controlled trial setting. These modes can easily be applied during colonoscopy and if demonstrated to be effective may save time and eliminate the need for dye-spray chromoendoscopy in the future.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria1

  • Patients with inflammatory bowel disease aged 18 to 75 years, that meet Australian recommendations to undergo surveillance colonoscopy will be identified and invited participate in the study.

Exclusion Criteria4

  • Any active disease
  • Inadequate bowel preparation
  • Previous surgical resection involving the colon
  • History of bowel cancer

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREImage Enhanced Endoscopy Filters

Patients that undergoing surveillance and consent to be involved in the study will be randomised to undergo surveillance with LCI, TXI or dye-spray chromoendoscopy (methylene blue).


Locations(1)

Royal Perth Hosptial

Perth, Western Australia, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06266104


Related Trials